Recent Updates
Recently added Catalysts

GEN1047 is a bispecific antibody that induces T-cell mediated cytotoxicity of B7H4-positive tumor cells

Phase 2

Breast Cancer, Breast Neoplasms | Monoclonal antibody | Oncology |Genmab A/S|Last Updated: Mar 2, 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLED
Total Trials1
Total Enrollment179

FDA Designations

No designations recorded

Clinical trial landscape

GEN1047 is a bispecific antibody that induces T-cell mediated cytotoxicity of B7H4-positive tumor cells · 1 trial · 4 indications

Phase 1/2 1
NCT05180474GEN1047 for Solid Tumors - First in Human (FIH) TrialBreast Cancer, Breast Neoplasms
ACTIVE NOT_RECRUITING179 Analytics
PHASE1/PHASE2ACTIVE NOT_RECRUITING
GEN1047 for Solid Tumors - First in Human (FIH) Trial
Breast Cancer, Breast NeoplasmsUnlock trial analytics

Study Design & Arms

Interventions

NameTypeDescription
GEN1047 is a bispecific antibody that induces T-cell mediated cytotoxicity of B7H4-positive tumor cells.BIOLOGICALGEN1047 will be administered as an intravenous infusion. The dose-levels will be determined by the starting dose and the escalation steps taken in the trial.
Unlock Study Design Details